Pharmacyte Biotech Inc. (PMCB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmacyte Biotech Inc. (PMCB:NASDAQ), powered by AI.

Current Price
$0.83
P/E Ratio
0.2
Market Cap
6M
Sector
Healthcare
What is the Pharmacyte Biotech Inc. stock price forecast?

Pharmacyte Biotech Inc. is currently trading at $0.83. View real-time AI analysis on Alpha Lenz.

What is Pharmacyte Biotech Inc. insider trading activity?

View the latest insider trading data for Pharmacyte Biotech Inc. on Alpha Lenz.

What is Pharmacyte Biotech Inc.'s P/E ratio?

Pharmacyte Biotech Inc.'s P/E ratio is 0.2.

Pharmacyte Biotech Inc.

NASDAQ · PMCB
$0.83+0.02(+2.16%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Pharmacyte Biotech Inc.'s future dividend policy...
Alpha Chat Insight

Pharmacyte Biotech Inc. trades at a P/E of 0.2 (undervalued) with strong ROE of 67.1%.

Ask for details

Company Overview

Pharmacyte Biotech Inc. is a biotechnology company focused on the development and commercialization of cellular therapies for cancer and diabetes management. Operating within the burgeoning biotech industry, the company's main objective is to harness leading-edge cellular therapy technologies to offer innovative treatment options. A notable feature of Pharmacyte Biotech Inc. is its proprietary Cell-in-a-Box technology, which is designed for the targeted delivery of chemotherapy drugs to tumor sites, aiming to enhance treatment efficacy while minimizing adverse effects. Furthermore, the company is actively exploring applications of its technology platform for treating diabetes by encapsulating genetically modified cells that can produce insulin. Pharmacyte Biotech Inc.'s advancements are significant in the asset's market, as they represent potential breakthroughs in addressing challenging medical conditions with unmet therapeutic needs. By collaborating with researchers and key players in the medical field, Pharmacyte Biotech Inc. seeks to make a substantial impact on healthcare outcomes through precision medicine and cutting-edge biotechnological solutions.

CEOMr. Joshua N. Silverman
SectorHealthcare
IndustryBiotechnology
Employees2

Company Statistics

FY 2025

Profile

$6.07MMarket Cap
$0.00Revenue
0.00Shares Out
2Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

0.20P/E
0.12P/B
N/AEV/Sales
0.24EV/EBITDA
-2.04P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

53.28%ROA
67.08%ROE
-7.61%ROIC

Financial Health

$15.17MCash & Cash Equivalents
$-11.89MNet Debt
6.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pharmacyte Biotech Inc. (ticker: PMCB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $6M.

The current price is $0.828 with a P/E ratio of 0.2x and P/B of 0.12x.

ROE is 67.08%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pharmacyte Biotech Inc. (PMCB) Stock Forecast 2026 $0.83 — Price, Financials & Analyst Targets | Alpha Lenz